TC BioPharm

United Kingdom
Holytown, Scotland, United Kingdom, ML1 4WQ

Company profile

TC BioPharm company profile

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

Business identity

Contact email
[email protected]
Phone number
+4401414337557
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
ML1 4WQ
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
16
Total equity funding
$62.8M
Last funding
Grant / $250,000 / 2024-11-12
Last equity funding
Post IPO Equity / $6M
Investors
9
Lead investors
5
Founders
4
Articles
139
Exited on
2022-02-11

Founders and investors

Founders

Angela ScottArtin MoussaviDavid GallagherMichael Leek

Lead investors

Genetix Biotherapeutics Inc.NCL Technology VenturesNipro CorporationScaleReadyScottish Enterprise

Investors

CrowdcubeGenetix Biotherapeutics Inc.Nipro CorporationScottish EnterpriseSyndicateRoom